Basic Pletal Information

• INN (International Nonproprietary Name): Cilostazol
• Brand Names Available in Australia: Pletal
• ATC Code: B01AC23
• Forms & Dosages: Tablets, 100 mg
• Manufacturers in Australia: Aspen Pharma Pty Ltd
• Registration Status in Australia: Registered by TGA
• OTC / Rx Classification: Prescription Only Medicine (Rx)

Latest Research Highlights

Recent studies have highlighted the effectiveness of cilostazol, particularly for managing intermittent claudication linked to peripheral arterial disease. One notable 2022 Australian study revealed robust improvements in walking distances for patients taking cilostazol compared to those on placebo. This aligns with findings from global research, reinforcing the idea that cilostazol can significantly enhance the quality of life for individuals suffering from this condition. The Therapeutic Goods Administration (TGA) in Australia diligently oversees cilostazol's safety and efficacy, assuring a commitment to patient care standards. According to the latest research, continuous administration for an initial period of 12 weeks has shown considerable benefits, advocating for adherence to established treatment protocols. **[Research Study Outcomes Table]**: Data on pharmacodynamics, patient demographics, and adverse effects observed in clinical trials is crucial for understanding cilostazol's impact.

Clinical Effectiveness in Australia

Cilostazol, marketed under the name Pletal, has demonstrated noteworthy health outcomes for patients receiving prescriptions through the Pharmaceutical Benefits Scheme (PBS). The data monitored by the TGA indicates a reduction in hospitalization rates for peripheral artery disease among patients who adhered to prescribed cilostazol treatments. Eighty per cent of patients in surveyed groups reported enhanced walking abilities shortly after commencing treatment, a testament to Australia's successful integration of these medications into standard care practices. Considering that education is a cornerstone of effective treatment, healthcare professionals are increasingly emphasising the importance of patient adherence, which contributes significantly to optimal health outcomes. **[Outcome Data Table]**: Detailed information on patient demographics, dosage adjustments, and recorded side effects is essential for practitioners to utilise cilostazol successfully. Patient stories shared in various forums highlight the tangible benefits of cilostazol, such as improved mobility and the ability to engage in daily activities, reflecting the Australian cultural emphasis on maintaining an active lifestyle.

Indications & Expanded Uses

Cilostazol, under TGA regulations, is principally indicated for the treatment of intermittent claudication associated with peripheral arterial disease. As research progresses, discussions around off-label uses are emerging, particularly in enhancing peripheral blood flow during certain surgical procedures. In Australia, healthcare providers are encouraged to base their prescribing decisions on evidence-based guidelines. This approach ensures informed choices are made for patients across different contexts. It's vital for patient education to highlight that off-label use of cilostazol must be considered cautiously, particularly in light of existing contraindications. **[Indication Summary List]**: A summary illustrating standard approved uses, along with notes on potential off-label prescription considerations, can assist in reinforcing proper prescribing practices. This adaptable framework not only prioritises the individual needs of patients but also ensures compliance with regulatory standards, thereby contributing to enhanced healthcare solutions.

Composition & Brand Landscape

Cilostazol, functioning as the active ingredient in Pletal, is predominantly available in Australia in tablet form with a strength of 100 mg. Under TGA regulations, while the packaging may vary, the active dosage is standardised across available products. Local brand names include Pletal, produced by Aspen Pharma Pty Ltd. The landscape of cilostazol in the international market has shifted recently, particularly with the rise of generic alternatives following the discontinuation of the brand in the US. This change allows for greater access to cilostazol for patients residing in Australia. **[Brand Comparison Table]**: An overview of different brand names and forms available globally can provide insights into the local market's availability. The competitive nature of this market presents both opportunities and challenges concerning accessibility for patients. It underscores the necessity for ongoing education to mitigate misconceptions relating to generic medications.

Conclusion

Overall, the evidence supporting cilostazol's effectiveness, particularly for conditions like intermittent claudication, is compelling. Continued research and patient education are paramount in enhancing understanding, accessibility, and adherence to treatment protocols in Australia.

Contraindications & Special Precautions

Cilostazol, widely recognised in Australia under the brand name Pletal, has a specific profile when it comes to safety and contraindications. The use of cilostazol is strictly prohibited in patients with any degree of heart failure. This restriction stems from a notable increase in mortality risk associated with its use in this demographic. It's crucial for healthcare professionals to maintain heightened vigilance when prescribing cilostazol to older adults, particularly within Indigenous populations, where unique health challenges may exist.

Patients with bleeding disorders or those suffering from active peptic ulcers require close monitoring when prescribed cilostazol. The risks associated with these conditions necessitate a cautious approach to patient management. Ongoing educational efforts are essential for both patients and healthcare practitioners, as awareness of these contraindications is fundamental to ensuring safe prescribing practices.

Adhering to these guidelines fosters a culturally sensitive approach to healthcare, which is particularly important for vulnerable populations, ensuring better outcomes and more tailored treatment paths.

Dosage Guidelines

When it comes to dosing cilostazol, the standard regimen is fairly straightforward. Typically, adults receive 100 mg taken orally, twice daily. For optimal absorption, it's recommended to take the medication 30 minutes before or two hours after meals. Australia's Therapeutic Goods Administration (TGA) advises clinicians to assess the efficacy of treatment after a minimum period of two to four weeks, with the full clinical effect expected after approximately 12 weeks.

In the presence of comorbid conditions such as liver impairment, healthcare providers are reminded to exercise caution. While standard dosage adjustments aren't commonly recommended, ongoing assessment for side effects and efficacy remains vital. Clinicians can refer to the Pharmaceutical Benefits Scheme (PBS) guidelines for specific advice regarding patient dosing.

Patient education plays a vital role in understanding the prescribed regimen. Ensuring that individuals comprehend their treatment empowers them to better manage their health effectively.

Interactions Overview

Potential drug interactions are a significant consideration for healthcare providers prescribing cilostazol. Educating patients about dietary restrictions is equally important, particularly regarding alcohol and caffeine consumption, both of which could amplify side effects like palpitations and dizziness. Additionally, cilostazol is known to interact with strong CYP3A4 and CYP2C19 inhibitors, which may complicate drug metabolism.

Regular evaluations of patient medication regimens help highlight any critical interactions, facilitating timely adjustments that enhance patient safety. This approach underscores the importance of thorough patient assessments in the context of cilostazol usage.

Taking these precautions into account strengthens the commitment to comprehensive patient care, ensuring safer use of cilostazol.

Cultural Perceptions & Patient Habits

The cultural perception of cilostazol within Australia reveals a blend of trust in healthcare providers alongside economic considerations regarding medication access, especially under the PBS. Many patients express a positive attitude towards healthcare advice, often valuing pharmacists as important sources of information when navigating treatment options.

However, regional differences are notable; rural patients frequently encounter barriers to accessing care compared to those in urban settings. Fortunately, the rise of telehealth services is bridging these gaps, enabling better access to necessary prescriptions and consultations.

These insights are instrumental in adapting healthcare delivery models to cater to the diverse needs of the Australian population. By recognising these cultural nuances, practitioners can enhance patient engagement and compliance, ultimately leading to better health outcomes.

Availability & Pricing Patterns

Pletal, known generically as cilostazol, is a prescription drug easily found at major Australian pharmacy chains. Chemist Warehouse, Priceline, and TerryWhite Chemmart stock this medication along with various online pharmacies that often provide competitive pricing.

For eligible patients, the Pharmaceutical Benefits Scheme (PBS) offers substantial cost reductions, making Pletal an affordable option for those who need it. This subsidy acts as a safety net, ensuring that patients with financial constraints can access necessary medication.

However, it's crucial for patients to be aware of the pricing variations that can exist between retail and online outlets. This disparity may encourage patients to explore various options, highlighting the pharmacists' role in delivering transparent pricing information.

Access to affordable medication is a cornerstone of healthcare equity in Australia. Informed patient decisions play a vital part in ensuring that this accessibility is maintained and maximised.

Comparable Medicines and Preferences

When it comes to treating intermittent claudication, options like pentoxifylline and naftidrofuryl provide alternative therapies. Evidence indicates that these medications can vary in efficacy and side effects, which is why clinicians must consider patient-specific factors when prescribing.

Many patients have personal preferences based on their previous experiences with medications. Discussions surrounding alternatives to Pletal are essential. These conversations empower patients and encourage informed choices regarding their treatment paths.

Encouraging shared decision-making not only builds trust between healthcare providers and patients but also empowers individuals to choose treatments that best align with their specific needs.

FAQ Section

1. What is Pletal used for?
Pletal, or cilostazol, is primarily prescribed for intermittent claudication to improve walking ability.

2. Can I buy Pletal over the counter?
No, Pletal requires a prescription in Australia.

3. What are the side effects of cilostazol?
Common side effects include headache, dizziness, and gastrointestinal disturbances.

4. How long does it take for Pletal to work?
Clinical effects can take up to 12 weeks of consistent use to manifest fully.

Guidelines for Proper Use

Australian pharmacists have a vital role in counselling patients regarding the use of cilostazol. Patients need to adhere to prescribed regimens and be aware of potential side effects. Effective communication helps patients navigate their treatment experiences and underscores the importance of follow-up consultations for ongoing care.

Customising guidance to meet each patient’s unique needs reinforces the value of personalised healthcare, ultimately leading to greater success in treatment outcomes.

Delivery Options for Pletal